Corindus Vascular Robotics, Inc. (CVRS: OTCQB) | Corindus Vascular Robotics, Inc. to Present at the 2015 Leerink Global Healthcare Conference

Corindus Vascular Robotics, Inc. to Present at the 2015 Leerink Global Healthcare Conference

Feb 06, 2015

OTC Disclosure News Service

Vascular Robotics
, Inc. [OTCQB: CVRS], a leading developer of
precision vascular robotics, announced today that its CEO, David M.
Handler, will present at the 2015 Leerink Global Healthcare Conference
on February 11 at 8:50am EST at The Waldorf Astoria Hotel in New York

About Corindus Vascular Robotics, Inc.

Vascular Robotics, Inc.
is a global technology leader in
robotic-assisted percutaneous coronary interventions (PCIs). The
company’s FDA-cleared CorPath 200 System is the first medical device
that offers interventional cardiologists PCI procedure control from a
radiation protective interventional cockpit. With the CorPath System,
Corindus Vascular Robotics brings robotic precision to PCI procedures to
help optimize clinical outcomes and minimize the costs associated with
complications through improper stent placement. Corindus stands behind
its product with its unique $1,000 hospital credit “One Stent Program.”
For additional information, visit,
and follow @CorindusInc.

This press release shall not constitute an offer to sell or a
solicitation of an offer to buy securities of Corindus Vascular
Robotics, Inc. (the “Company”).
Certain statements in
this release, including the health hazards tied to interventional
cardiology, the reduction in radiation resulting from the use of the
CorPath System, the PCI procedure control from the interventional
cockpit, the optimization of clinical outcomes and the minimization of
costs associated with complications through improper stent placement,
and other written or oral statements made by or on behalf of the Company
are “forward-looking statements” within the meaning of the federal
securities laws. Statements regarding future events and developments and
our future performance, as well as management’s expectations, beliefs,
plans, estimates or projections relating to the future are
forward-looking statements within the meaning of these laws. The
forward-looking statements are subject to a number of risks and
uncertainties including FDA and market acceptance of the Company’s
products and the Company’s continued access to capital and other risks
and uncertainties identified in the Company’s Current Report on Form
8-K/A, Amendment No. 1, filed with the Securities and Exchange
Commission (SEC) on August 15, 2014 and the Company’s Registration
Statement on Form S-1, Amendment No. 4, filed with the SEC on January
14, 2015.
The actual results the Company achieves may differ
materially from any forward-looking statements due to such risks and
uncertainties. These statements are based on our current expectations
and speak only as of the date of such statements. The Company undertakes
no obligation to publicly update or revise any forward-looking
statement, whether as a result of future events, new information or

Copyright © 2015 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.